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Abstract
Objective: HMG-CoA reductase inhibitors (statins) possess anti-inflammatory and immunomodulatory properties that are independent
of their lipid-lowering action. As the CD40–CD40L signaling pathway is implicated in the modulation of inflammatory responses
between vascular cells, involving adhesion molecules, pro-inflammatory cytokines, chemokines, we sought to investigate the potential role
of statins in regulating the expression of CD40. Methods and Results: Using Western blot, flow cytometry and immunohistochemistry
analyses, we observed that four different statins reduced IFN-g-induced CD40 expression in human vascular cells (endothelial cells,
smooth muscle cells, macrophages and fibroblasts). This effect was dose-dependent (from 5 mM to 80 nM) and reversed by addition of
L-mevalonate. Activation of vascular cells by human recombinant CD40L, as measured by ELISA for IL-6, IL-8 and MCP-1, was strongly
reduced when cells were treated with statins. Immunostaining of human carotid atherosclerotic lesions of patients subjected to statin
treatment revealed less CD40 expression on a ‘per vascular cell’ basis compared to control patients. Although many pleiotropic effects of
statins are mediated by nitric oxide synthase (NOS)- or peroxisome proliferator-activated receptor (PPAR)-dependent signaling pathways,
we observed similar statin-induced reduction of CD40 expression using NOS inhibitors or different PPAR ligands. Conclusion: Statins
decrease CD40 expression and CD40-related activation of vascular cells. These effects are partially reversed by the HMG-CoA reductase
product L-mevalonate and are mediated by NOS- or PPAR-dependent pathways. Altogether, these findings provide mechanistic insight
into the beneficial effects of statins on atherogenesis. They also provide a scientific rationale for the use of statins as immunomodulators
after organ transplantation.
  2003 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
Keywords: Atherosclerosis; Cytokines; Immunology; Lipid metabolism; Receptors
1 . Introduction that these drugs greatly reduce cardiovascular-related
morbidity and mortality in patients with and without
Statins are effective lipid-lowering agents, extensively coronary disease [2,3]. Recently, in vitro and in vivo
used in medical practice [1]. They are competitive in- findings have indicated that statins, beside their lipid-
hibitors of 3-hydroxy-3-methylglutaryl coenzyme A lowering effects, possess anti-inflammatory properties [4].
(HMG-CoA) reductase, an enzyme crucial for cholesterol In addition, we recently demonstrated that these drugs
synthesis. Several large clinical trials have demonstrated might also be recognized as a new type of immuno-
suppressor [5].
Atherosclerosis is considered as an immuno-inflamma-
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central role for the CD40–CD40L signaling pathway in the bodies for IL-6, IL-8 and MCP-1 were obtained from
pathogenesis of this disease [8,9]. Recently, two reports R&D. L-Mevalonate was purchased from Sigma (St. Louis,
demonstrated that hypercholesterolemia, one of the major MO, USA). Human recombinant CD40 ligand (rCD40L)
cardiovascular risk factors, increases CD40 and CD40L was generated as described previously [17]. L-NAME was
expression on platelets and monocytes [10] as well as purchased from Sigma. 15d-PGJ was obtained from2
plasma levels of soluble CD40L [11]. In addition, it has Calbiochem (La Jolla, CA, USA), ETYA from Sigma,
been shown that blocking CD40–CD40L interactions WY14643 from Biomol (Plymouth Meeting, PA, USA),
significantly prevents the development of atherosclerotic and Troglitazone a gift from Park Davis Pharmaceuticals
plaques and reduces already pre-established lesions (Morris Plains, NJ, USA).
[12,13]. Moreover, CD40 signaling has been implicated in
other chronic disorders such as rheumatoid arthritis, multi- 2 .2. Cells
ple sclerosis and allograft rejection following organ trans-
plantation [14]. The investigation conforms with the principles outlined
CD40L (recently renamed CD154) and CD40 are mem- in the Declaration of Helsinki (Cardiovasc Res 1997;35:2-
bers of the tumor necrosis factor (TNF) and TNF-receptor 3) as well as the Guide for the Care and Use of
family, respectively. The original function of CD40L in T Laboratory Animals published by the US National Institute
cell-dependent humoral immunity involves the activation of Health (NIH publication No. 85-23, revised 1996).
and differentiation of B-lymphocytes, the switching of Human vascular ECs and SMCs were isolated from
immunoglobulin classes as well as the formation of saphenous veins and cultured as described previously
germinal center and memory cells. More recently, activa- [5,18]. Primary human fibroblasts were isolated from nasal
tion of vascular cells such as macrophages (MF), endo- polyps and cultured as previously described [19]. Cells
thelial cells (ECs) and smooth muscle cells (SMCs) via were used at passages two to four for all experiments.
CD40 signaling has been shown to induce inflammatory Human monocytes were obtained from peripheral blood of
responses with expression of adhesion molecules and healthy donors as described previously [20]. They were
secretion of pro-inflammatory cytokines, chemokines, ma- grown in RPMI 1640 medium containing 10% fetal calf
trix metalloproteinases and tissue factor [15]. All these serum (FCS) for 10 days. The human Raji cell line was
molecules are known to be crucial in the pathogenesis of obtained from ATCC (Rockville, MD, USA).
atherosclerosis as well as during graft-versus-host disease.
In view of the large clinical beneficial effects of statins 2 .3. Western blot analysis
on cardiovascular morbidity and mortality, and the emer-
gence of numerous non-lipid lowering anti-inflammatory Cells were harvested in ice-cold radio-immuno-precipi-
effects of these drugs, we sought to investigate whether tation assay (RIPA) solubilization buffer, and total amounts
statins regulate the expression of CD40 in vascular cells. of protein determined using a bicinchoninic acid quantifi-
cation assay (Pierce, Rockford, IL, USA). Western blotting
was performed as described before [5]. Blots were blocked
2 . Methods in 5% defatted dry milk /phosphate-buffered saline (PBS) /
0.1% Tween, incubated for 1 h at room temperature with
2 .1. Reagents primary antibody (1:40; rabbit polyclonal anti-CD40), or
mouse monoclonal anti-human b-actin (1:5000; Pharming-
Human and mouse recombinant IFN-g were obtained en) as control of loading, followed by 1 h incubation with
from Endogen (Cambridge, MA, USA) and R&D Systems secondary antibody (1:10,000; Jackson ImmunoResearch).
(Abingdon, UK), respectively. The statins used in these Quantification was performed using AIDA software
studies, i.e. atorvastatin, simvastatin, lovastatin and pravas- (Raytest, Urdorf, Switzerland).
tatin were obtained from commercial sources. Because
ECs lack lactonases, to process simvastatin and lovastatin 2 .4. Flow cytometry
to their active forms, these agents were chemically acti-
vated before their use as previously described [16]. Mouse Cells were incubated with FITC-conjugated specific
anti-human CD40 monoclonal antibody fluorescein iso- antibody (60 min, 4 8C) and analyzed in a Becton Dickin-
thiocyanate-conjugated (FITC) and mouse anti-human son FACScan flow cytometer as described [5]. At least
HLA-DR monoclonal antibody (FITC) were obtained from 100,000 viable cells were analyzed per condition. Data
Pharmingen (San Diego, CA, USA). Rabbit anti-human were analyzed using CELLQUEST software (Becton Dic-
CD40 polyclonal antibody, anti-rabbit IgG FITC, and HRP kinson).
(horseradish peroxidase) goat anti-rabbit IgG were pur-
chased from Santa Cruz (Santa Cruz, CA, USA), Jackson 2 .5. Cytokine assays
ImmunoResearch (West Grove, PA, USA) and Vector
Laboratories (Burlingame, CA, USA), respectively. Anti- Release of IL-6, IL-8 and MCP-1 was measured using a
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sandwich-type enzyme-linked immunosorbent assay snap-frozen in liquid nitrogen. There was no significant
(ELISA) according to the manufacturer’s instructions difference for age, gender, cardiovascular risk factors and
(R&D). Experiments were performed in the presence of other medications between patients treated or not with
polymyxin B (1 mg/ml). Optical density was measured at simvastatin (Table 1). Serial cryostat sections (5 mm) were
450 nm using a Dynatech plate reader (Chantilly, VA, cut, air dried onto microscope slides (Fisher Scientific,
USA). The amount of IL-6, IL-8 and MCP-1 detected was Wohlen, Switzerland), and fixed in acetone at 220 8C for 5
calculated from a standard curve prepared with the recom- min. Sections were pre-incubated with blocking buffer
binant protein. Samples were assayed in duplicate. (PBS/Tween with 8% normal horse serum) and then
incubated successively with an anti-human CD40 antibody
2 .6. Fluorescence immunolabeling for 1 h. Thereafter, sections were incubated with
biotinylated secondary antibody (45 min; Vector Laborator-
Monocytes /macrophages grown on coverslips were ies) followed by avidin–biotin–alkaline phosphatase com-
rinsed and fixed for 15 min with paraformaldehyde (4%). plex (Vectastain ABC kit). Antibody binding was visual-
Coverslips were rinsed and cells incubated successively in ized by alkaline phosphatase substrate (Vector Laborator-
0.5 M NH Cl/PBS for 15 min and PBS supplemented with ies). Quantitative analyses for CD40 and CD68 expression4
2% bovine serum albumin (Sigma) for a further 20 min. were performed with a computer-based color image analy-
Human macrophages were incubated overnight with pri- sis system [21].
mary rabbit polyclonal anti-CD40 (1:50) in 10% normal
goat serum (Sigma) /PBS. After rinsing, human macro- 2 .8. Statistical analysis
phages were incubated with secondary antibodies FITC-
conjugated (1:800) for 3 h. All steps were performed at Data are presented as mean6S.E.M. Mean values
room temperature and between incubation steps cells were between two groups were compared using a two-tailed
rinsed with PBS. Finally, coverslips were mounted on Student’s t-test, after having performed an F-test for
slides in Vectashield (Vector Laboratories). Cells were homogeneity of variances. If data failed to meet require-
examined using a Zeiss Axiophot microscope. Replace- ments for use of the parametric t-test, a Mann–Whitney
ment of the primary antibody with PBS/10% normal goat U-test was used. Differences were considered statistically
serum was used to control the specificity of the immuno- significant at P,0.05.
labeling of human macrophages.
2 .7. Immunohistochemistry 3 . Results
Surgical specimens of human carotid atheroma were 3 .1. Statins reduce CD40 expression on vascular cells
obtained by protocols approved by the Review Committee
at the University Hospital of Geneva. All atherosclerotic To determine whether statins influence CD40 expres-
carotid specimen analyzed were obtained from patients sion, human vascular endothelial cells (ECs) were acti-
treated (for at least 3 months) or not with the simvastatin. vated with human recombinant IFN-g (1000 U/ml /24 h)
Materials were directly embedded in OCT compound or in the presence or absence of atorvastatin, lovastatin,
pravastatin or simvastatin. As previously described, un-
stimulated vascular cells showed little expression of CD40,
T able 1 which was greatly induced by IFN-g [18]. Western blot
Baseline characteristics of patients in the simvastatin and control groups
analysis (Fig. 1A) revealed that statin treatment reduced
Simvastatin (n518) Control (n514) both, basal CD40 expression as well as IFN-g-induced
CD40. Simvastatin appeared to be the most potent inhib-Age (years) 68 65
Sex (F/M) 8/10 8/6 itor, followed by lovastatin, pravastatin and atorvastatin
Diabetes (%) 32 38 (Fig. 1A). Raji cells, known to express a large amount of
Smokers (%) 34 30 CD40, were used as positive control (Fig. 1A, lane 8). TheHypertension (%) 73 68
reduction of CD40 expression by statins was dose-depen-Medication (%)
dent (Fig. 1B). The concentration range (0.08 to 10 mM)Aspirin 33 28
ACEIs 45 48 of statins used in these experiments was similar to earlier
b-Blockers 24 22 reports [5,22], and neither cell survival nor protein syn-
Anti-diabetic agents 33 38 thesis was affected at these concentrations (data notDiuretics 32 21
shown). Interestingly, simvastatin treatment significantly
reduced CD40 expression (Fig. 1B) at a concentration ofTotal cholesterol (mmol / l) 5.3 (61.3) 6.4 (61.4)
LDL-c, 3.3 (61.1) 4.1 (61.2) only 80 nM, which corresponds to the effective serum
HDL-c 1.3 (60.3) 1.2 (60.3) levels seen with statin treatment in clinical practice [23].
Triglycerides 1.9 (61.4) 2.3 (61.4) These effects of statins on CD40 expression were specific
758 F. Mulhaupt et al. / Cardiovascular Research 59 (2003) 755–766
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for the inhibition of the HMG-CoA reductase enzyme, under statin therapy expressed much less CD40 compared
since addition of L-mevalonate largely reversed the statin- to control patients (Fig. 4A, B). In addition, we observed
induced inhibition of CD40 expression (Fig. 1A). Similar that individual macrophages within lesions from statin-
results were obtained for human vascular SMCs (Fig. 1C). treated patients showed markedly less CD40 expression
These results were confirmed using flow cytometry analy- compared to individual macrophages in lesions of control
sis (Fig. 1D). Western blot results were supported by patients (Fig. 4C). This reduction was mainly detected
immunohistochemical analysis on human monocyte– within the shoulder region of the atherosclerotic plaques.
macrophages (Fig. 2A–F) and on human fibroblasts (Fig.
2G–I), two other cell types present in atherosclerotic 3 .4. Statin reduction of CD40 expression is neither
lesions. Taken together, these experiments demonstrate mediated via nitric oxide nor via PPARs
that statin treatment decreased CD40 expression on all
human vascular cells tested. Due to numerous recent reports demonstrating that
several anti-inflammatory effects of statins could be largely
3 .2. Statins inhibit functional CD40 signaling related to their ability to stabilize and increase nitric oxide
synthase (NOS) [25], we investigated whether statins
To examine functional consequences of statin treatment reduce CD40 expression via NOS pathways. To address
on CD40 expression, we stimulated vascular cells with this question, we stimulated human ECs with recombinant
human recombinant CD40 ligand (rCD40L) in the presence IFN-g and simvastatin in the presence or absence of the
or absence of the statins. As presented in Fig. 3 for ELISA NOS inhibitor L-NAME. As shown in Fig. 5 by flow
experiments on ECs, rCD40L induced the secretion of the cytometry analysis, the level of CD40 expression after
pro-inflammatory molecules IL-6, IL-8 and MCP-1, as statin treatment was similarly reduced with or without
previously described [17,24]. When stimulated in the L-NAME treatment.
presence of the statins, the synthesis and secretion of all Furthermore, as statins have been recently reported to
these pro-inflammatory proteins were largely reduced. As activate PPARs [26], we investigated whether PPAR
previously described, statins also reduced constitutive ligands could regulate CD40 expression on human vascular
cytokine secretion, these effects were however not statisti- cells. We did not detect any effect of either PPAR-a or
cally significant. The statin-induced reduction in cytokine / PPAR-g ligands on CD40 cell surface expression following
chemokine secretion was partially reversed by the addition IFN-g activation (Fig. 6). These findings indicate that
of L-mevalonate (Fig. 3A–C). Specificity of these experi- neither NOS nor PPARs are involved in the reduction of
ments was confirmed by blocking CD40–CD40L signaling CD40 expression by statins on vascular cells.
with the addition of an anti-CD40L antibody (Fig. 3C).
3 .3. Statin treatment decreases CD40 expression within 4 . Discussion
human atherosclerotic tissue
Increasing evidence supports the central role of the
In view of our findings that statins reduce CD40 CD40–CD40L signaling pathway in atherosclerosis. Acti-
expression and CD40 signaling in vitro, we decided to vation of vascular cells via CD40–CD40L interactions has
explore the expression of CD40 on vascular cells within been shown to induce inflammatory responses with expres-
human atherosclerotic lesions obtained from patients sion of adhesion molecules, secretion of pro-inflammatory
treated or not with simvastatin (20 mg/day for at least 3 cytokines, matrix metalloproteinases, tissue factor and
months). Baseline patients characteristics were not statisti- chemokines [8,9,18], molecules considered as crucial
cally different and are shown in Table 1. Immunohistoch- players in atherogenesis. Recent in vitro and in vivo
emical in situ and Western blot analyses of human carotid findings suggest that statins also have anti-inflammatory
arteries revealed that atherosclerotic lesions from patients properties [24,27]. Statins inhibit HMG-CoA reductase that
Fig. 1. Statins decrease IFN-g-induced CD40 expression on human endothelial cells. (A–C) Western blot analysis for CD40. (A) Human vascular ECs
under unstimulated conditions (1); treated with IFNg (1000 U/ml, 24 h) alone (2); or in the presence of atorvastatin (10 mM) (3); lovastatin (10 mM) (4);
pravastatin (20 mM) (5); simvastatin (10 mM) (6); or simvastatin (10 mM) and L-mevalonate (400 mM) (7); Raji cells under unstimulated condition as
positive control (8). *P,0.05 (compared to 2); **P,0.05 (compared to 6). Quantification of Western blots is expressed as ratio of CD40/b-actin signal
for each samples. (B) Human vascular ECs under unstimulated conditions (Ctrl), or treated with IFNg (1000 U/ml, 24 h) alone; or in the presence of
simvastatin (5 to 0.08 mM). b-actin is shown as loading control. (C) Human vascular SMCs under unstimulated conditions (1), treated with IFNg (500
U/ml, 24 h) alone (2); or in the presence of simvastatin (10 mM) (3). b-actin is shown as loading control. (D) Flow cytometry analysis for CD40. Human
vascular ECs treated with IFNg (1000 U/ml, 24 h) alone (green line); or in the presence of simvastatin (5 mM) (blue line). Expression of MHC class II for
ECs stimulated with IFNg (1000 U/ml, 24 h) is shown as positive control (red line). Shown is a histogram representing cell numbers ( y-axis) vs. CD40 log
fluorescence intensity (x-axis) for 20,000 viable cells, and ECs under unstimulated conditions are shown (solid histograms) as well as isotype controls
(dotted lines). For all analysis, similar results were obtained in separate experiments using cells from four different donors.
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Fig. 2. Statins reduce CD40 expression on human macrophages and fibroblasts. Immunohistochemical analysis of CD40 expression (green fluorescence).
Macrophages (A–F) and fibroblasts (G–I). Cells were counterstained with Evans Blue (red color). (A) Cells under unstimulated conditions. (B) Cells
treated with IFN-g alone (1000 U/ml, 24 h); or in the presence of simvastatin (5 mM) (C); simvastatin (1 mM) (D); or pravastatin (20 mM) (E). (F) Cells
treated with IFN-g (1000 U/ml, 24 h) and stained with secondary antibody only (negative control). (G) Cells under control conditions; treated with IFN-g
alone (500 U/ml, 24 h) (H); or in the presence of simvastatin (10 mM) (I). Scale bar represents 50 mm. Similar results were obtained in separate
experiments using cells from three different donors.
transforms HMG-CoA into mevalonate. Indeed, as mevalo- CD40–CD40L in atherogenesis as well as the pleiotropic
nate is not only the precursor of cholesterol but also of effects of statins in this disease, we sought to investigate in
many non-steroidal isoprenoids, statins may regulate the vitro and in vivo the effect of statins on CD40 expression
expression and activities of important molecules in the as well as on related CD40 activation in human vascular
pathogenesis of atherosclerosis. Given the importance of cells.
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 showed that the reduction of CD40 expression by statins is
not mediated via mevalonate synthesis, but are in agree-
ment with three other recent reports [10,29,30].
All four statins used in this study reduce IFN-g-induced
CD40 expression: simvastatin being the strongest, fol-
lowed by lovastatin, pravastatin and atorvastatin. Although
other in vitro studies have also revealed differences in
potency of individual statins, these results should be
interpreted with great care. One possible explanation for
the strong effect of simvastatin on IFN-g-induced CD40
expression might be that this specific statin possesses
additional anti-inflammatory effects through inhibitory
actions in other signaling pathways. Alternatively, simply
due to different pharmacokinetic properties simvastatin
may be more effectively processed by cells in culture. It is
of importance to note in this respect that in vivo in mouse
models both atorvastatin and simvastatin are effective
treatments against multiple sclerosis and rheumatoid arth-
ritis [30,31].
CD40 signaling plays a critical role in the initiation of
the immune response by inducing inflammatory responses
with secretion of pro-inflammatory cytokines and
chemokines. These chemokines probably attract and direct
T lymphocytes and macrophages to the atheroma, thus
sustaining chronic inflammation [32,33]. Indeed, lack of
chemoattractants or their receptors is known to signifi-
cantly diminish atherosclerotic lesion progression in mice
[34,35]. We found that statin treatment influences func-
tional cellular CD40 signaling by reducing the release of
cytokines and chemokines. By secreting these pro-inflam-
matory mediators and growth factors, vascular cells canFig. 3. Statins reduce CD40 function on CD40L-activated human vascu-
lar endothelial cells. IL-6 (A), IL-8 (B) and MCP-1 (C) releases measured promote the migration and proliferation of SMCs. In
by ELISA in supernatants of ECs exposed (24 h) to normal media (1); response to inflammatory stimulation, SMCs and MF
simvastatin (10 mM) alone (2); activated by rCD40L (5 mg/ml) alone
secrete MMPs that will subsequently degrade matrix(3); or in the presence of atorvastatin (10 mM) (4); lovastatin (10 mM)
compounds of the plaque as well as other inflammatory(5); simvastatin (10 mM) (6), or simvastatin (10 mM) and L-mevalonate
mediators that inhibit collagen synthesis. As extracellular(400 mM) (7); rCD40L (5 mg/ml) preincubated with polyclonal CD40L
antibody (8). Similar results were obtained in independent experiments matrix components are considered crucial determinants of
with ECs from four different donors. *P,0.05 (compared to 3); **P, fibrous cap integrity and stability, statin-induced reduction
0.05 (compared to 6); ***P,0.05 (compared to 3).
of CD40 signaling with consequent reduction in secretion
of pro-inflammatory cytokines and chemokines may not
Pro-inflammatory cytokines expressed within atheroma only exert beneficial actions on progression of atheros-
provide a chemotactic stimulus to adherent leukocytes, clerotic plaque development but on the composition of the
directing their migration into the intima. Our data show by plaque as well. Indeed, one of the major complications in
different techniques that statin treatment largely reduces clinical cardiology is plaque rupture with local thrombus
CD40 expression both on human ECs and on monocyte– formation, potentially leading to acute coronary
macrophages, thereby potentially reducing EC–monocyte syndromes.
interactions. Similar results were obtained on murine Interruption of CD40–CD40L interactions by adminis-
macrophages (data not shown). Importantly, we observed a tration of anti-CD40L blocking antibody or gene targeting
reduction of CD40 expression at a concentration of 80 nM, has been shown to prevent atherogenesis and limit the
which is within the range of effective serum concentrations progression of established atherosclerotic lesions in mice
seen in clinical practice [23]. In addition, L-mevalonate [12,13]. Both strategies have resulted in a decrease in
largely reversed the statin-induced decreased in CD40 pro-inflammatory factors and an increase in collagen
expression, indicating that indeed the inhibition of HMG- content of atherosclerotic lesions. Recently, it has been
CoA reductase mediates the statin-induced repression of shown that in a short prospective treatment period statins
CD40 on vascular cells. These results are partly in reduced the pro-inflammatory state of human atheromatous
contradiction with the data from Wagner et al. [28], which lesions [36]. Our results showing that patients under statin
762 F. Mulhaupt et al. / Cardiovascular Research 59 (2003) 755–766
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therapy express less CD40-positive cells within atheros- deed, clinical studies have suggested a better outcome after
clerotic plaques compared to control patients without statin cardiac transplantation in patients subjected to statin
therapy. In addition, they show that individual macro- therapy [39,40]. We recently demonstrated that statins are
phages express less CD40, suggesting direct effects of involved in the immune response by inhibiting IFN-g
statins on macrophages in vivo. induced MHC-II [5], and thus might be used as immuno-
Most of the anti-inflammatory effects of statins have modulators. In addition, CD40 has been shown to play a
been related to their ability to stabilize and increase NO crucial role in graft-versus-host disease [41,42]. Our
synthase [4,22]. This endogenous vasodilator molecule has current findings indicating that statins decrease CD40
by itself anti-inflammatory properties [37]. However, our expression on antigen presenting cells may therefore
experiments illustrate that the reduction of CD40 expres- provide a new scientific rationale for their use as immuno-
sion after statin treatment does not involve the NOS modulators following organ transplantation.
signaling pathway. Recently, statins have been reported to In summary, we show that statins decrease CD40
activate PPARs [26]. In addition, we recently reported that expression in vascular cells in vitro as well as in vivo. By
PPAR-g-induced repression of major histocompatibility reducing CD40 expression and signaling, statins may
complex class II (MHC-II), another molecule involved in reduce inflammation and thus stabilize atherosclerotic
the immune response [38]. We did not detect an effect of plaques, features believed to account for the beneficial
either PPAR-a or PPAR-g ligands on CD40 cell surface effects of statins on cardiovascular morbidity and mortali-
expression following IFN-g activation, thus excluding also ty. Our findings not only provide an additional explanation
these signaling pathways from mediating statin-induced for previously unknown non-lipid effects of statins in
reduction in CD40 expression. atherogenesis, but also suggest their application in further
One of the major problems following organ transplanta- immuno-inflammatory diseases in which CD40 is in-
tion is the development of graft-versus-host disease. In- volved, such as multiple sclerosis, systemic lupus erythe-
 
Fig. 5. Statins effect on CD40 expression is not mediated through NOS. Flow cytometry analysis for CD40 expression. Human vascular ECs treated with
IFNg (1000 U/ml, 24 h) alone (green line); or with simvastatin (5 mM) (blue line); or in the presence of simvastatin (5 mM) and L-NAME (5 mM) (red
line). Shown is a histogram representing cell numbers ( y-axis) vs. CD40 log fluorescence intensity (x-axis) for 20,000 viable cells, and ECs under
unstimulated conditions are shown (solid histograms) as well as isotype controls (dotted lines). Similar results were obtained in independent experiments
with ECs from three different donors.
Fig. 4. Statin therapy decreases CD40 expression on human atherosclerotic lesions. (A) Representative photomicrographs (3100) of CD40 expression (red
color) within human carotid atherosclerotic lesions in situ. Atherosclerotic lesion in patient treated (1) or not (2) by statin therapy. L, lumen of the vessel.
Quantitative analysis of CD40 expression on atherosclerotic lesions obtained from patients treated with statin (1) (n518), or without statin therapy (2)
(n514) is shown on the right side of this panel. *P,0.05. (B) Western blot analysis of human carotid atherosclerotic tissues obtained from patients treated
(1) or not (2) with statin therapy. Quantitative analysis of CD40 expression in patients treated with statin (1) (n512), or without statin therapy (2)
(n510) is shown on the right side of this panel. *P,0.05. (C) Double immunofluorescence stain for macrophages (CD68) in green and CD40 in red in
patient treated (1) or not (2) by statin therapy. *P,0.05. Similar results were obtained in separate experiments using tissues from five different donors.
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Fig. 6. Effects of PPAR ligands on IFN-g-induced CD40 expression on human endothelial cells. Flow cytometry analysis for CD40 expression. Human vascular endothelial cells (ECs) treated with
IFN-g (500 U/ml, 24 h) alone (green line), or with the PPAR-g ligands (red lines) 15d-PGJ (10 mmol/ l) (A), Troglitazone (50 mmol / l) (B); or with the PPAR-a ligands (red lines) ETYA (50 mmol / l)2
(C), and WY14643 (50 mmol / l) (D). Each panel is a histogram representing cell numbers ( y-axis) vs. log fluorescence intensity (x-axis) for 15,000 viable cells, and ECs under unstimulated conditions
are shown (solid histograms) as well as isotype controls (dotted lines). Similar results were obtained in independent experiments with ECs from five different donors.
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